Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | Chief Development Officer | March 01, 2024 | April 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pasithea Therapeutics Corp.
Report date March 01, 2024 · Filed April 06, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2034-02-28 | Direct | 5,938 |
Reported balance
After 2024-03-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-01 · Grant · Acquired 5,938 · Balance 5,938 F1: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. F2: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
F2: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 2, 2024 02:45 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 5,938 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001213900-24-019216 · ownership.xml · derivative · entry 1 Currie Graeme Martin · CIK 0001965006 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,938 Underlying: Common Stock · 5,938 shares Expires 2034-02-28 F1 · derivative.exercise_date: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024. Read SEC document |
| March 01, 2024 Filed Apr 6, 2024 01:45 UTC Amendment | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 5,938 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001213900-24-030959 · ownership.xml · derivative · entry 1 Currie Graeme Martin · CIK 0001965006 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,938 Underlying: Common Stock · 5,938 shares Expires 2034-02-28 F1 · derivative.exercise_price: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. F2 · derivative.exercise_date: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.